Anti-tubercular screening of natural products from Colombian plants: 3-methoxynordomesticine, an inhibitor of MurE ligase of Mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 10, 2010, Pages 2101-2107

  Guzman, Juan D ^a,b,c,d   Gupta, Antima ^a   Evangelopoulos, Dimitrios ^a   Basavannacharya, Chandrakala ^a   Pabon, Ludy C ^b   Plazas, Erika A ^b   Muñoz, Diego R ^b   Delgado, Wilman A ^b   Cuca, Luis E ^b   Ribon, Wellman ^c,e   Gibbons, Simon ^d   Bhakta, Sanjib ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^c INSTITUTO NACIONAL DE SALUD   (Colombia)

^d UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

Author keywords

Aporphine alkaloids; MurE inhibitors; TB

Indexed keywords

2',4',6' TRIMETHOXYDIHYDROCHALCONE; 3 METHOXYNORDOMESTICINE HYDROCHLORIDE; APORPHINE DERIVATIVE; AUSTROBAILIGNAN 6; BOLDINE; DIHYDROGUAIARETIC ACID; GIBBILIMBOL B; N METHOXYCARBONYL 3 METHOXYNORDOMESTICINE; NATURAL PRODUCT; PHOSPHATE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTITUBERCULAR ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CARBON NUCLEAR MAGNETIC RESONANCE; COLOMBIA; COLORIMETRY; CYTOTOXICITY; DRUG ACTIVITY; DRUG ISOLATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; ESCHERICHIA COLI; LIQUID CULTURE; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BIOLOGICAL PRODUCTS; COLOMBIA; COLORIMETRY; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; ESCHERICHIA COLI; HUMANS; LIGASES; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; PEPTIDE SYNTHASES; PLANT EXTRACTS; PLANTS;

EID: 77957222136     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq313     Document Type: Article

References (34)

1. Cole ST. Comparative and functional genomics of the Mycobacterium tuberculosis complex. Microbiology 2002; 148: 2919-28.
2. Donoghue HD, Lee OY-C, Minnikin DE et al. Tuberculosis in Dr Granville's mummy: a molecular re-examination of the earliest known Egyptian mummy to be scientifically examined and given a medical diagnosis. Proc R Soc Lond B Biol Sci 2010; 277: 51-6.
3. WHO. Global Tuberculosis Control: A Short Update to The 2009 Report. Geneva: WHO, 2009.
4. Brewer TF, Heymann SJ. To control and beyond: moving towards eliminating the global tuberculosis threat. J Epidemiol Community Health 2004; 58: 822-5.
5. Hehenkamp A, Hargreaves S. Tuberculosis treatment in complex emergencies: South Sudan. Lancet 2003; 362: s30-s1.
6. Lienhardt C, Ogden JA. Tuberculosis control in resource-poor countries: have we reached the limits of the universal paradigm? Trop Med Int Health 2004; 9: 833-41.
7. Casenghi M, Cole ST, Nathan CF. New approaches to filling the gap in tuberculosis drug discovery. PLoS Med 2007; 4: 1722-5.
8. Gonzalez-Lamothe R, Mitchell G, Gattuso M et al. Plant antimicrobial agents and their effects on plant and human pathogens. Int J Mol Sci 2009; 10: 3400-19.
9. Bednarek P, Osbourn A. Plant-microbe interactions: chemical diversity in plant defense. Science 2009; 324: 746-8.
10. Gibbons S. Anti-staphylococcal plant natural products. Nat Prod Rep 2004; 21: 263-77.
11. Copp BR, Pearce AN. Natural product growth inhibitors of Mycobacterium tuberculosis. Nat Prod Rep 2007; 24: 278-97.
12. Pabon LC, Cuca LE. Aporphine alkaloids from Ocotea macrophylla (Lauraceae). Quim Nova 2010; 33: 875-9.
13. Guzman JD, Isaza JH, Cuca LE. Fragmentacion diastereoespecifica en NCI de dos lignanos dibencilbutanicos de la corteza de Dugandiodendron argyrotrichum (Magnoliaceae). Rev Prod Nat 2008; 2: 6-12.
14. Guzman JD, Cuca LE. Metabolitos secundarios aislados de Dugandiodendron argyrotrichum Lozano (Magnoliaceae). Rev Col Quim 2008; 37: 275-88.
15. Plazas EA, Delgado W, Cuca LE. Flavonoides aislados de las inflorescencias de Piper hispidum Kunth (Piperaceae) y derivados acetilados. Rev Col Quim 2008; 37: 135-44.
16. Basavannacharya C, Robertson G, Munshi T et al. ATP-dependent MurE ligase in Mycobacterium tuberculosis: biochemical and structural characterisation. Tuberculosis 2010; 90: 16-24.
17. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
18. Jana M, Luong T-T, Komatsuzawa H et al. A method for demonstrating gene essentiality in Staphylococcus aureus. Plasmid 2000; 44: 100-4.
19. Anishetty S, Pulimi M, Pennathur G. Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis. Comput Biol Chem 2005; 29: 368-78.
20. Orjala J, Mian P, Rali T et al. Gibbilimbols A-D, cytotoxic and antibacterial alkenylphenols from Piper gibbilimbum. J Nat Prod 1998; 61: 939-41.
21. Mshana RN, Tadesse G, Abate G et al. Use of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide for rapid detection of rifampin-resistant Mycobacterium tuberculosis. J Clin Microbiol 1998; 36: 1214-9.
22. Palomino JC, Martin A, Camacho M et al. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 2720-2.
23. Evangelopoulos D, Bhakta S. Rapid methods for testing inhibitors of mycobacterial growth. In: Antibiotic Resistance Protocols, Methods in Molecular Biology. London: Humana Press, 2010; 193-201.
24. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Fifth Edition: Approved Standard M7-A5. NCCLS, Wayne, PA, USA, 1999.
25. Gupta A, Bhakta S, Kundu S et al. Fast-growing, non-infectious and intracellularly surviving drug-resistant Mycobacterium aurum: a model for high-throughput antituberculosis drug screening. J Antimicrob Chemother 2009; 64: 774-81.
26. Talorete T, Bouaziz M, Sayadi S et al. Influence of medium type and serum on MTT reduction by flavonoids in the absence of cells. Cytotechnology 2006; 52: 189-98.
27. Mata R, Morales I, Perez O et al. Antimycobacterial compounds from Piper sanctum. J Nat Prod 2004; 67: 1961-8.
28. Nimgirawath S, Udomputtimekakul P, Taechowisan T et al. First total syntheses of (±)-isopiline, (±)-preocoteine, (±)-oureguattidine and (±)-3-methoxynordomesticine and the biological activities of (±)-3-methoxynordomesticine. Chem Pharm Bull 2009; 57: 368-76.
29. Rivero-Cruz I, Acevedo L, Guerrero J et al. Antimycobacterial agents from selected Mexican medicinal plants. J Pharm Pharmacol 2005; 57: 1117-26.
30. Li G, Lee C-S, Woo M-H et al. Lignans from the bark of Machilus thunbergii and their DNA topoisomerases I and II inhibition and cytotoxicity. Biol Pharm Bull 2004; 27: 1147-50.
31. Kawaguchi Y, Yamauchi S, Masuda K et al. Antimicrobial activity of stereoisomers of butane-type lignans. Biosci Biotech Biochem 2009; 73: 1806-10.
32. Lu H, Tonge PJ. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Accounts Chem Res 2008; 41: 11-20.
33. Mahapatra S, Crick DC, McNeil MR et al. Unique structural features of the peptidoglycan of Mycobacterium leprae. J Bacteriol 2008; 190: 655-61.
34. Minnikin DE, Kremer L, Dover LG et al. The methyl-branched fortifications of Mycobacterium tuberculosis. Chem Biol 2002; 9: 545-53.